My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 553

    1.

    Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.

    Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman OG, Chandran M, Mudaliar SR, Henry RR.

    Diabetes Care. 2003 Jan;26(1):1-8.PMID: 12502651 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

    Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG.

    Diabetes Care. 2003 Nov;26(11):3074-9.PMID: 14578242 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.

    Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG.

    Horm Metab Res. 2002 Sep;34(9):504-8.PMID: 12384827 [PubMed - indexed for MEDLINE]Related articles

    4.

    Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.

    Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG.

    Diabetes Care. 2003 Mar;26(3):784-90.PMID: 12610038 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.

    Fineman MS, Koda JE, Shen LZ, Strobel SA, Maggs DG, Weyer C, Kolterman OG.

    Metabolism. 2002 May;51(5):636-41.PMID: 11979398 [PubMed - indexed for MEDLINE]Related articles

    6.

    Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.

    Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, Ruggles JA, Kolterman OG, Weyer C.

    Diabetes Metab Res Rev. 2004 Jan-Feb;20(1):55-60.PMID: 14737746 [PubMed - indexed for MEDLINE]Related articles

    7.

    Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.

    Chase HP, Lutz K, Pencek R, Zhang B, Porter L.

    J Pediatr. 2009 Sep;155(3):369-73. Epub 2009 May 21.PMID: 19464026 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.

    Kolterman OG, Schwartz S, Corder C, Levy B, Klaff L, Peterson J, Gottlieb A.

    Diabetologia. 1996 Apr;39(4):492-9.PMID: 8778001 [PubMed - indexed for MEDLINE]Related articles

    9.

    Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.

    Singh-Franco D, Robles G, Gazze D.

    Clin Ther. 2007 Apr;29(4):535-62. Review.PMID: 17617279 [PubMed - indexed for MEDLINE]Related articles

    10.

    The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.

    Nyholm B, Orskov L, Hove KY, Gravholt CH, Møller N, Alberti KG, Moyses C, Kolterman O, Schmitz O.

    Metabolism. 1999 Jul;48(7):935-41.PMID: 10421239 [PubMed - indexed for MEDLINE]Related articles

    11.

    Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.

    Ryan GJ, Jobe LJ, Martin R.

    Clin Ther. 2005 Oct;27(10):1500-12. Review.PMID: 16330288 [PubMed - indexed for MEDLINE]Related articles

    12.

    Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes.

    Ceriello A, Piconi L, Quagliaro L, Wang Y, Schnabel CA, Ruggles JA, Gloster MA, Maggs DG, Weyer C.

    Diabetes Care. 2005 Mar;28(3):632-7.PMID: 15735200 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes.

    Heptulla RA, Rodriguez LM, Bomgaars L, Haymond MW.

    Diabetes. 2005 Apr;54(4):1100-7.PMID: 15793249 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Continuous glucose monitoring in children with type 1 diabetes: before and after insulin pump therapy.

    Heptulla RA, Allen HF, Gross TM, Reiter EO.

    Pediatr Diabetes. 2004 Mar;5(1):10-5.PMID: 15043684 [PubMed - indexed for MEDLINE]Related articles

    15.

    Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus.

    Hassan K, Heptulla RA.

    Pediatr Diabetes. 2009 Jun;10(4):264-8. Epub 2008 Dec 18.PMID: 19140902 [PubMed - indexed for MEDLINE]Related articles

    16.

    A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.

    Edelman S, Garg S, Frias J, Maggs D, Wang Y, Zhang B, Strobel S, Lutz K, Kolterman O.

    Diabetes Care. 2006 Oct;29(10):2189-95.PMID: 17003291 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.

    Rodriguez LM, Mason KJ, Haymond MW, Heptulla RA.

    Pediatr Res. 2007 Dec;62(6):746-9.PMID: 17957149 [PubMed - indexed for MEDLINE]Related articles

    18.

    Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.

    Raz I, Weiss R, Yegorchikov Y, Bitton G, Nagar R, Pesach B.

    Clin Ther. 2009 May;31(5):980-7.PMID: 19539098 [PubMed - indexed for MEDLINE]Related articles

    19.

    Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.

    Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG.

    Diabet Med. 2004 Nov;21(11):1204-12.PMID: 15498087 [PubMed - indexed for MEDLINE]Related articles

    20.

    Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes.

    Wysham C, Lush C, Zhang B, Maier H, Wilhelm K.

    Curr Med Res Opin. 2008 Jan;24(1):79-85.PMID: 18031595 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity